In a registered starting material dossier submitted under ICH Q11 Section 5.2.1, the compound functions as the immediate precursor to the sulfonylurea active moiety. The specification assigned to the material must cross-reference Ph. Eur. 2.2.46 chromatographic separation as well as USP 〈621〉, with acceptance criteria for any individual unknown impurity not exceeding 0.10%. During the downstream condensation with trans-4-methylcyclohexyl isocyanate, the stoichiometric ratio is maintained at 1:1.05 (intermediate:isocyanate) in anhydrous dichloromethane at 20–25°C under a nitrogen blanket. The resulting solution is quenched with 1.0 N HCl, the organic phase washed until conductivity falls below 50 µS/cm, and the crude product crystallized from isopropanol/water 70:30 v/v after treatment with activated carbon. Final API particle size is reduced through a Quadro Comil U5 fitted with a 0.039-inch screen, targeting a D90 of <100 µm to ensure blend uniformity in direct-compression formulations. Finished dosage forms derived from this synthesis pathway are 1 mg, 2 mg, 3 mg, 4 mg, and 6 mg glimepiride tablets, where the API crystallizes exclusively as the thermodynamically stable Form I identified by XRPD per Ph. Eur. 5.2.8.
Uncontrolled cis-Isomer Content Exceeding 0.15%: A Manufacturing Bottleneck in Polymorph Selection
When the intermediate carries ≥0.15% of the cis-3-ethyl-4-methyl isomer, the subsequent addition reaction with the cyclohexyl isocyanate yields the corresponding cis-glimepiride impurity at levels capable of altering the nucleation kinetics of the desired trans-API. In production-scale crystallizers equipped with retreat-curve impellers and jacket temperature ramps of 0.3°C/min, the cis impurity concentration above 0.12% consistently depresses the metastable zone width by 4–7°C, triggering spontaneous primary nucleation that results in agglomerated Form II crystals with a residual solvent burden exceeding ICH Q3C options for Class 2 solvents. Process validation batches therefore enforce a receiving limit of ≤0.10% cis isomer by the Ph. Eur. monograph method, employing a Kromasil Eternity XT 5 µm, 250×4.6 mm column with a mobile phase of acetonitrile:buffer 45:55 at 1.2 mL/min and detection at 228 nm. If the intermediate shipment deviates, an additional isopropanol:water 65:35 reslurry at 55°C for 6 hours is implemented prior to the main reaction to strip the cis species to <0.05%. The final polymorph identity is verified by DSC endotherm onset at 207±2°C and compliance with the IR spectrum reference in the EDQM certified reference standard, ensuring the final product aligns with the 1 mg–6 mg tablet presentations listed in all major pharmacopoeias.
Bioequivalence study protocols submitted under 21 CFR 320.24 require a validated LC-MS/MS method in which the subject compound serves as a stable-isotope-labeled internal standard analogue after deuteration at the ethyl side chain. The working reference solution is prepared at a concentration of 100 ng/mL in acetonitrile:water 50:50 with 0.1% formic acid, and calibration standards span 0.5–500 ng/mL in pooled human K3-EDTA plasma. Extraction follows a protein precipitation procedure with 400 µL of acetonitrile per 200 µL of plasma, followed by centrifugation at 14,000 rpm for 10 minutes at 4°C. The supernatant is evaporated under nitrogen at 40°C and reconstituted in 100 µL of mobile phase. Chromatography is executed on an Agilent 1290 Infinity II UHPLC coupled to a Sciex QTRAP 6500+ with a Waters XBridge BEH C18 2.5 µm, 2.1×50 mm column; the gradient program separates glimepiride from the hydroxylated metabolite M1 and the carboxylic acid metabolite M2 within 7.5 minutes. The method withstands ICH M10 validation criteria: intra-run precision at the LLOQ does not exceed 18.7% CV and accuracy ranges between 89.3–107.8% across all QC levels. Regulatory submissions anchored to these data support final dosage forms ranging from 1 mg to 8 mg glimepiride tablets manufactured under EU GMP Part II, with the certified reference standard lot linked to a valid ISO 17034 certificate.
What Limits the Recoverable Yield When the Intermediate is Shipped with a Residual Triethylamine Load Above 300 ppm?
Triethylamine, employed as an acid scavenger in the preceding acylation step, becomes problematic if its concentration in the shipment exceeds 300 ppm as determined by headspace GC-FID per USP 〈467〉. During the phase of carbamoylation with isocyanate, residual tertiary amine catalyzes an exothermic dimerization side-pathway that generates a bis-sulfonylurea adduct, detectable as a late-eluting peak at RRT 1.73 in the HPLC chromatogram monitored at 230 nm. Reaction calorimetry data from a Mettler Toledo RC1e reactor, operating in isothermal mode at 25°C with a 1 L glass vessel, show that a triethylamine load of 450 ppm increases the heat release rate from 2.3 W/kg to 11.8 W/kg within 12 seconds of isocyanate addition, rapidly exceeding the jacket cooling capacity in piped-loop systems of 10,000 L glass-lined vessels. The immediate countermeasure is a pre-wash of the incoming batch with 0.05 M aqueous acetic acid at a volume ratio of 5:1 (solvent:intermediate), followed by three deionized water washes until the aqueous phase conductivity drops below 10 µS/cm. Process control limits set the triethylamine ceiling at ≤100 ppm for direct use without pre-treatment, aligning with the residual solvent Option 2 levels in ICH Q3C for Class 3 solvents. The downstream isolation sequence—nutsche filtration, delumping through a conical mill, and vacuum drying at 45°C and –0.08 MPa for 8 hours—consistently delivers an API that meets the tightest heavy metal specifications of Ph. Eur. monograph 1923, and is subsequently compressed into 1 mg, 2 mg, 3 mg, and 4 mg scored tablets with a friability of <0.8%.
Parallel Library Enumeration Using the Sulfonamide Core: Reagent Stoichiometrics in Automated Synthesis Workstations
Drug discovery groups engaged in sulfonylurea receptor SUR1 modulation deploy this intermediate in array formats to generate focused libraries of N-acylurea analogues and N-arylurea replacements. On a Chemspeed SWING platform equipped with 16-mL glass reactors and overhead vortex agitation at 900 rpm, each reaction vessel receives 0.25 mmol of intermediate dissolved in 2.0 mL of anhydrous N,N-dimethylacetamide. A 1.2-equivalent excess of the chosen isocyanate, distributed from a pre-tared syringe pump at a flow rate of 0.5 mL/min, is introduced under a continuous nitrogen sweep to keep headspace moisture below 50 ppm. The reactions are left to proceed at 30°C for 18 hours and then quenched with 500 µL of methanol. Crude purity by UPLC-UV at 225 nm typically ranges from 72–96%, with the preparative HPLC purification triggered automatically for fractions below 90% purity using a Waters AutoPurification system with a Sunfire C18 OBD 5 µm, 19×150 mm column and a 20–95% acetonitrile/water gradient over 12 minutes. All synthesized compounds are registered in a centralized electronic lab notebook compliant with 21 CFR Part 11, and their biological activities are screened against the human SUR1 receptor in a fluorescence-based membrane potential assay. Although these screening compounds never enter human dosing, the structure-activity relationship data directly inform the design of back-up candidates that, after salt and polymorph screening, could become development candidates for 1–4 mg once-daily oral dosage forms targeting Type 2 diabetes mellitus. The entire automated process aligns with the non-clinical quality guidelines in ICH Q7 for investigational medicinal products, with the intermediate's specification sheet referencing ISO 9001:2015 and the relevant EU REACH registration number of the manufacturer.
During a forced degradation study conducted to support the photostability section per ICH Q1B Option 2, the intermediate is intentionally stressed under 1.2 million lux·hours of visible light and 200 W·h/m² of UV radiation in a Suntest CPS+ chamber. The resulting photodegradants, including the N-oxide derivative at RRT 1.32 and the desulfonamidated cleavage product at RRT 0.78, are isolated via semi-preparative chromatography on a YMC-Pack Pro C18 10 µm, 20×250 mm column at a flow rate of 15.0 mL/min. These purified impurity markers are then characterized by high-resolution mass spectrometry on a Thermo Scientific Q Exactive HF-X, with mass accuracy maintained at <2 ppm, and by 1H-NMR (600 MHz, DMSO-d6) to confirm structure. The characterized standards are diluted to 0.1% (w/v) relative to the API test concentration for system suitability evaluation against the Ph. Eur. acceptance table that mandates resolution of ≥2.5 between glimepiride and the cis-isomer peak. The customer receives these impurity standards with a certificate of analysis compliant with ISO/IEC 17025:2017, and the relative response factors established in this protocol are applied during the batch release testing of 1 mg, 2 mg, 3 mg, 4 mg, and 6 mg glimepiride tablet lots for markets regulated under Annex 13 of EU GMP for investigational medicinal products.
